Professur für Innere Medizin (Nephrologie)

Excellent efficacy and beneficial safety during observational 5-year follow-up of rapid steroid withdrawal after renal transplantation (Harmony FU study) (2024) Stumpf J, Thomusch O, Opgenoorth M, Wiesener M, Pascher A, Woitas RP, Suwelack B, et al. Journal article Hypoxia controls expression of kidney-pathogenic MUC1 variants (2023) Naas S, Krüger R, Knaup K, Naas J, Grampp S, Schiffer M, Wiesener M, Schödel J Journal article Prevalence of hereditary tubulointerstitial kidney diseases in the German Chronic Kidney Disease study (2022) Popp B, Ekici AB, Knaup K, Schneider K, Uebe S, Park J, Bafna V, et al. Journal article Detecting tandem repeat variants in coding regions using code-adVNTR (2022) Park J, Bakhtiari M, Popp B, Wiesener M, Bafna V Journal article An intermediate-effect size variant in UMOD confers risk for chronic kidney disease (2022) Olinger E, Schaeffer C, Kidd K, Elhassan EA, Cheng Y, Dufour I, Schiano G, et al. Journal article Noninvasive Diagnosis of Acute Rejection in Renal Transplant Patients Using Mass Spectrometric Analysis of Urine Samples: A Multicenter Diagnostic Phase III Trial (2022) Gwinner W, Karch A, Braesen JH, Khalifa AA, Metzger J, Naesens M, Van Loon E, et al. Journal article The renal cancer risk allele at 14q24.2 activates a novel hypoxia-inducible transcription factor-binding enhancer of DPF3 expression (2022) Protze J, Naas S, Krüger R, Stöhr C, Kraus A, Grampp S, Schiffer M, et al. Journal article Estrogen-mediated downregulation of HIF-1 alpha signaling in B lymphocytes influences postmenopausal bone loss (2022) Meng X, Lin Z, Cao S, Janowska I, Sonomoto K, Andreev D, Knab K, et al. Journal article Diverse molecular causes of unsolved autosomal dominant tubulointerstitial kidney diseases (2022) Wopperer F, Knaup K, Stanzick KJ, Schneider K, Jobst-Schwan T, Ekici AB, Uebe S, et al. Journal article Monitoring complement biomarkers in C3 glomerulopathy patients with factor H or FHR gene mutations before and after treatment with eculizumab or ravulizumab (2022) Vanderliek K, Afonso S, Loeschmann I, Krebs C, Wiech T, Skerka C, Zipfel P, Wiesener M Conference contribution